CBCE - Activity Details

Ninth Annual New Strategies in Breast Cancer Conference

Philadelphia, PA
April 3 - 4, 2009

Program Description
Program Description
In this 2-day intensive review, clinical experts will discuss recent progress in the detection, prevention, diagnosis, and treatment of breast cancer. Interactive discussions and didactic presentations will cover the latest advances in imaging, radiotherapeutic, surgical, and pharmacotherapeutic strategies, as well as supportive care of patients undergoing treatment for breast cancer.

Benefits:

Opportunity to interact and share information with colleagues and clinical experts
Condensed format that covers the most relevant developments in the care of patients with breast cancer

Target Audience
This activity is designed for medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, physician assistants, and other healthcare professionals interested in the care of patients with breast cancer.

Educational Objectives
Upon completion of this activity, participants will be able to

Evaluate the results of recent studies on molecular profiling of breast cancer and consider how such tools can be used to determine the best treatment options for patients with breast cancer.
Assess the efficacy of neoadjuvant regimens recently tested in clinical trials for the treatment of patients with breast cancer and discuss treatments benefits.
Discuss novel surgical and radiotherapy techniques designed to maximize patient benefit while minimizing risks and/or adverse effects in patients with breast cancer.
Describe the clinical endpoints that are currently accepted for gaining FDA approval as well as the limitations of using OS as an endpoint in clinical trials for breast cancer.
Evaluate the results of recent clinical trials that investigate novel targeted and chemotherapeutic agents as well as regimens for the treatment of patients with breast cancer.
Summarize how advances in breast cancer screening, diagnosis, and prevention may decrease morbidity and mortality in patients at high risk for developing the disease.
Evaluate recent and ongoing trials that examine endocrine therapy in patients with breast cancer.
Determine appropriate strategies for identifying and managing patients with HER2-overexpressing breast cancer.
Assess the use of bisphosphonates in the management of patients with breast cancer.

Method of Participation
This conference will use multiple methods of participation, including lectures, interactive discussions, didactic presentations, and panel discussions to engage attendees and enhance the learning process.

Accreditation
Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The CBCE designates this educational activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 11.0 hours of Category 1 credit for completing this program.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The CBCE designates this educational activity for 11.0 contact hours.

Accreditation by the American Nurses Credentialing Center’s Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
CPE Credit: 11 contact hours or 1.10 CEUs
Universal Program Number: 195-000-09-006-L01-P

Certificate
The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after the CBCE receives their form.

Acknowledgement of Commercial Support
The CBCE gratefully acknowledges the educational grants provided by AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Centocor Ortho Biotech Services Inc.; and sanofi-aventis. Please visit www.thecbce.com for a current list of supporters.

Americans With Disabilities Act (ADA)
The CBCE fully complies with the legal requirements of the Americans With Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff at the conference registration desk.

Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com

Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Centocor Ortho Biotech Services, LLC; or sanofi-aventis. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this program.

Conference Cancellation Policy
If a cancellation notice is received in writing by March 13, 2009, 75% of the registration fee will be refunded. All cancellation requests should be sent to the CBCE.

Chair(s)

Dennis J. Slamon, MD, PhD
Chief, Division of Hematology/Oncology
Director of Clinical/Translational Researc
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, CA

George W. Sledge Jr, MD
Ballvé-Lantero Professor of Oncology
Professor of Medicine and Pathology
Co-Director, Indiana University Breast Cancer Center
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, IN

Faculty

Alan Ashworth, FRS
Director, Breakthrough Breast Cancer Research Center
Institute of Cancer Research
London, United Kingdom

Leslie Bernstein, PhD
Professor
City of Hope Comprehensive Cancer Center
Duarte, CA

Angela H. Brodie, PhD
Professor of Pharmacology and Experimental Therapeutics
Department of Pharmacology
University of Maryland School of Medicine
Baltimore, MD

Adam Brufsky, MD, PhD
Associate Professor
Associate Chief, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, PA

Susan M. Domchek, MD
Associate Professor of Medicine
Director, Cancer Risk Evaluation Program
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, PA

Fransisco J. Esteva, MD, PhD
Associate Professor
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Stephen R. Johnston, MA, PhD, FRCP
Director of Clinical Research and Development
Director of NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust and Institute of Cancer Research
London, United Kingdom

Henry M. Kuerer, MD, PhD, FACS
Director, Breast Surgical Oncology Training Program
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Terry P. Mamounas, MD, MPH, FACS
Professor of Surgery
Northeastern Ohio Universities College of Medicine
Canton, OH

Hyman B. Muss, MD
Professor of Medicine
University of Vermont
Vermont Cancer Center, Hematology/Oncology Unit
Burlington, VT

Susan G. Orel, MD
Professor of Radiology, Breast Imaging
University of Pennsylvania
Philadelphia, PA

Ann H. Partridge, MD, MPH
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Malcolm C. Pike, PhD
University Professor, Preventative Medicine
Keck School of Medicine
Norris Comprehensive Cancer Center
University of Southern California
Los Angeles, CA

Lajos Pusztai, MD, DPhil
Associate Professor
Department of Breast Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Peter M. Ravdin, MD, PhD
Research Professor
San Antonio, TX

Andrew Seidman, MD
Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, NY

Lawrence J. Solin, MD, FACR
Chairman, Department of Radiation Oncology
Albert Einstein Medical Center
Philadelphia, PA

Deborah Toppmeyer, MD
Associate Professor of Medicine
The Cancer Institute of New Jersey
New Brunswick, NJ

Frances M. Visco
President
National Breast Cancer Coalition
Washington, DC

Max Wicha, MD
Distinguished Professor of Oncology
Director
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Eric P. Winer, MD
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Friday, April 03 2009

Session I
Session II
Session III
Session IV
Session V
Session VI
8:00 - 8:10 AM	Welcome, Introductions, and Pre-Activity Assessment Questions	George W. Sledge, Jr
8:10 - 8:40 AM	Keynote Lecture: Targeting Triple Negative Breast Cancer	Alan Ashworth
8:40 - 8:45 AM	Question-and-Answer Session
8:45 - 9:05 AM	Cost/Benefit Analysis of MRI Testing	Susan G. Orel
9:05 - 9:25 AM	Genetic Susceptibility and Breast Cancer	Susan M. Domchek
9:25 - 9:45 AM	Epidemiology and Current Standards in Cancer Prevention	Leslie Bernstein
9:45 - 10:05 AM	Stem Cell Biology and Clinical Relevance in Breast Cancer	Max Wicha
10:05 - 10:25 AM	Breast Cancer Prevention	Malcolm C. Pike
10:25 - 10:40 AM	Panel Discussion
10:40 - 10:55 AM	Break
10:55 - 11:15 AM	Endpoints of Clinical Trials: The Patient Perspective	Frances M. Visco
11:15 - 11:30 AM	Question-and-Answer Session
11:30 - 11:50 AM	Hormonal Therapy: State of the Art	Steven R. D. Johnston
11:50 AM - 12:10 PM	New Directions in Aromatase Inhibitor–Based Therapies for Early and Advanced Breast Cancer	Angela H. Brodie
12:10 - 12:30 PM	Emerging Strategies for the Management of Bone Integrity in Patients With Metastatic Breast Cancer	Adam Brufsky
12:30 - 12:50 PM	New Approaches and Genomic Profiling Patterns of Hormonal Responses	Alan Ashworth
12:50 - 1:05 PM	Panel Discussion
1:05 - 1:50 PM	Lunch
1:50 - 2:10 PM	Prognostic Factors for Local Recurrence After Breast Conservation Treatment With Radiation	Lawrence J. Solin
2:10 - 2:30 PM	Surgery in the Era of Biologic Therapy for Breast Cancer	Henry M. Kuerer
2:30 - 2:45 PM	Panel Discussion
2:45 - 3:05 PM	Prognosis and Prediction in Breast Cancer	Peter M. Ravdin
3:05 - 3:25 PM	Genomics in Breast Cancer	Lajos Pusztai
3:25 - 3:40 PM	Panel Discussion
3:40 - 4:00 PM	Quality of Life in Long-Term Survivorship Issues	Ann H. Partridge
4:00 - 4:15 PM	Question-and-Answer Session

Saturday, April 04 2009

Session VII
Session VIII
8:00 - 8:10 AM	Welcome and Introductions	Dennis J. Slamon
8:10 - 8:40 AM	Keynote Lecture: Considerations in the Management of the Elderly Patient with Breast Cancer	Hyman B. Muss
8:40 - 8:55 AM	Question-and-Answer Session
8:55 - 9:15 AM	Preoperative Systemic Therapy for Breast Cancer: Progress and Continuing Controversies	Terry P. Mamounas
9:15 - 9:35 AM	HER2-Overexpressing Disease: What's New in Testing?	Dennis J. Slamon
9:35 - 9:50 AM	Antiangiogenic Therapy in Early and Advanced Disease	George W. Sledge, Jr
9:50 - 10:05 AM	Panel Discussion
10:05 - 10:20 AM	Break
10:20 - 10:40 AM	Biology and Treatment of Brain Metastases	Eric P. Winer
10:40 - 11:00 AM	Trastuzumab Resistance in HER2-Overexpressing Metastatic Breast Cancer: What Is It and How Do We Treat It?	Francisco J. Esteva
11:00 - 11:20 AM	Incorporating New Chemotherapy Agents in Metastatic Breast Cancer: Which Patients, Which Drugs?	Andrew Seidman
11:20 - 11:40 AM	Future Targets in Metastatic Breast Cancer	Deborah Toppmeyer
11:40 - 11:55 AM	Panel Discussion
11:55 AM - 12:10 PM	Evaluation Completion
12:10 - 12:10 PM	Adjourn

Philadelphia, PA

The Rittenhouse Hotel
210 West Rittenhouse Square
Philadelphia, PA 19103
www.rittenhousehotel.com

Conference Room Rate
Room accommodations for this conference are $260 per night, single or double occupancy, with an approximate 14% tax. There will be an additional charge of $25 per day for each additional person over the age of 18. The maximum number of people per guest room is 4. A maximum of 2 children under the age of 18 per room may stay free of charge.

Reservation Guarantee
An early response is suggested for guests desiring the group rate. To ensure the group rate, reservations must be made through the CBCE by Friday, February 27, 2009. After February 27, 2009, no guarantee is provided for accommodation availability or our room rate at The Rittenhouse Hotel.* Room type and group room rate are subject to availability. Check-in time is 3:00 PM; check-out time is 1:00 PM. All reservations must be guaranteed with a 1-night room deposit or a major credit card. A credit card is necessary to guarantee a late arrival. All major credit cards are accepted by The Rittenhouse Hotel. *If needed, the CBCE will make appropriate overnight accommodations for you at a nearby property (subject to availability).

Hotel Cancellation Policy
No-shows will be charged the full amount of the reservation. Any guaranteed rooms cancelled less than 14 days prior to the day of arrival will be charged the 1-night deposit amount. If the hotel is able to resell the reservation, you will not be charged the cancellation fee.
Climate
The climate in Philadelphia, Pennsylvania, in April is cool with temperatures ranging from an average daily low of 44°F to an average daily high of 62°F. A light sweater or jacket is recommended.

Limousine and Rental Car Services
Reservations can be made through The Rittenhouse Hotel concierge by calling (215) 546-9000.

Parking
Valet and visitor parking are available for $28 per day.

Taxi
If you wish to take a taxi to the hotel, expect an approximate $20 fare from the Philadelphia (PHL) Airport.